Provided by Tiger Trade Technology Pte. Ltd.

Charles River Laboratories

281.67
+8.263.02%
Post-market: 281.670.00000.00%19:55 EDT
Volume:809.84K
Turnover:228.71M
Market Cap:13.45B
PE:-57.70
High:285.58
Open:280.11
Low:274.40
Close:273.41
52wk High:303.31
52wk Low:144.26
Shares:47.74M
Float Shares:47.20M
Volume Ratio:0.82
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8814
EPS(LYR):-2.9122
ROE:-7.52%
ROA:4.11%
PB:4.74
PE(LYR):-96.72

Loading ...

Charles River Laboratories International Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Charles River Exec Says Any Decision to Expand China Structure Will Be Based on Cost, Demand, Growth Rates and Geopolitical Considerations

THOMSON REUTERS
·
May 07

Charles River Exec Says Recent Increase in Biopharma M&a Activity Has Provided Additional Source of Capital Infusion and Exit Strategy for Biotechs

THOMSON REUTERS
·
May 07

Charles River Exec Says Demand From Start-up Biotechs Remains Tepid as Earlier Stage and Seed Funding Environment Remains Constrained

THOMSON REUTERS
·
May 07

Charles River Exec Says Improved Demand in China Seen as Indication That Chinese Market Is Rebounding and Accelerating

THOMSON REUTERS
·
May 07

Charles River Exec Says Co Closely Monitoring China Market Given Accelerated Drug Innovation and in-Licensing Activity but Also Looking at Geopolitical Risks

THOMSON REUTERS
·
May 07

Charles River Exec Says Government Funding Pressures at Nih Have Modestly Impacted Client Spending

THOMSON REUTERS
·
May 07

Charles River Exec Says Revenue From Global Biopharmaceutical Client Segment Increased in the First Quarter - Conf Call

THOMSON REUTERS
·
May 07

Charles River beats quarterly estimates on steady demand for drug development services

Reuters
·
May 07

GUIDANCE: (CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08

MT Newswires Live
·
May 07

Charles River Q1 Adjusted EPS USD 2.06 Vs. IBES Estimate USD 1.94

Reuters
·
May 07

Charles River Q1 revenue and adjusted EPS beat estimates

Reuters
·
May 07

Charles River Q1 FY26 turns to net loss of $14.8 million; revenue rises 1.2% to $995.8 million

Reuters
·
May 07

Charles River Q1 Adj. EPS $2.06 Beats $1.94 Estimate, Sales $995.830M Beat $977.486M Estimate

Benzinga Earnings
·
May 07

Charles River Laboratories International Inc - Reaffirms 2026 Guidance for Organic Revenue and Non-Gaap Earnings per Share

THOMSON REUTERS
·
May 07

Charles River Outlook FY Revenue Growth -5.5 to -4%

THOMSON REUTERS
·
May 07

Charles River Laboratories International - Expects to Complete Sale of Certain European Discovery Services Sites in May 2026

THOMSON REUTERS
·
May 07

Press Release: Pharming Group reports first quarter 2026 financial results; on track for Joenja(R) U.S. pediatric label expansion and launches in Japan and Europe in 2026

Dow Jones
·
May 07

Charles River Laboratories International Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
May 07

Charles River Laboratories International Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
May 05